Higher levels of SIX3 were associated with decreased tumor proliferation and metastasis, leading to better survival outcomes and/or prognosis in breast cancer (Zheng et al., 2018), astrocytoma (Yu et al., 2017), glioblastoma (Zhang B. et al., 2017), and lung adenocarcinoma (Mo et al., 2013). This evidence concerns the gene SIX3 and neoplasm.